You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. LIXTE BIOTECHNOLOGY HOLDINGS INC

Lixte Biotechnology Holdings Inc XNAS: LIXT

Lixte Biotechnology Holdings Inc Live Share Price Today, Share Analysis and Chart

Download real time

1.26 -0.04 (-3.08%)

64.71% Fall from 52W High

22,240 XNAS Volume

XNAS 24 Apr, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share
Durability score
Not Eligible
-
Valuation Score
Expensive Valuation
0.0 / 100
Momentum Score
Technically Bearish
31.9 / 100
Analyst Price Target
No estimates available

7

S

7

W

0

O

1

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Lixte Biotechnology Holdin... Live Price Chart

Switch to TradingView
Fetching data ...

Lixte Biotechnology Holdin... Stock Analysis

Lixte Biotechnology Holdin... stock analysis with key metrics, changes, and trends.

Lixte Biotechnology Holdin... MetricVALUECHANGE %TRENDANALYSIS
Annual Net Profit$3.59 M29.51%positive

Annual Net Profit rose 29.51% in the last year to $3.59 M. Its sector's average net profit growth for the last fiscal year was -32.47%.

Price to Earning Ratio-0.94-negative

Price to Earning Ratio is -0.94, which is negative.

Stock Price$1.26-60.87%negative

Stock Price fell 60.87% and underperformed its sector by 72.25% in the past year.

Quarterly Net profit$0.62 M40.16%positive

Quarterly Net profit rose 40.16% YoY to $0.62 M. Its sector's average net profit growth YoY for the quarter was -41.99%.

Mutual Fund Holding0.86 %-0.04%negative

Mutual Fund Holding decreased by 0.04% in the last quarter to 0.86.

Interest Coverage Ratio-212.18-negative

Interest Coverage Ratio is -212.18, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding11.23 %0%neutral

Institutional Holding remained the same in the last quarter at 11.23%.

VIEW LESS


Loading data..

Lixte Biotechnology Holdings Inc - Company Profile

What does Lixte Biotechnology Holdings Inc do?

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Lixte Biotechnology Holdings Inc Management structure

All Gross Remunerations are in USD
Dr. James S. Miser, M.D.
Chief Medical Officer
-
2024
Gross Remuneration
Year
Dr. Jan H.M. Schellens
Chief Medical Officer
-
2024
Gross Remuneration
Year
Mr. Eric J. Forman, J.D.
Vice President and Chief Operating Officer
-
2024
Gross Remuneration
Year

Lixte Biotechnology Holdings Inc Board of directors

All Gross Remunerations are in USD
Dr. Yun Yen, M.D.
Independent Director
78.13 K
2023
Gross Remuneration
Year
Ms. Regina Brown
Independent Director
78.13 K
2023
Gross Remuneration
Year
Mr. Bastiaan van der Baan
Chairman of the Board, President and Chief Executi
66.61 K
2023
Gross Remuneration
Year
Dr. John S. Kovach
Executive Chairman of the Board and Chief Scientif
-
2023
Gross Remuneration
Year
Dr. Stephen J. Forman
Independent Director
-
2023
Gross Remuneration
Year
Dr. Rene Bernards
Independent Director
-
2023
Gross Remuneration
Year

Lixte Biotechnology Holdings Inc FAQ

How is Lixte Biotechnology Holdings Inc today?
Lixte Biotechnology Holdings Inc today is trading in the red, and is down by -3.08% at 1.26.
Lixte Biotechnology Holdings Inc is currently trading down -3.08% on an intraday basis. In the past week the stock rose 2.44%. stock has been down -48.57% in the past quarter and fell -60.87% in the past year. You can view this in the overview section.